… type EGFR and patients with EGFR mutations respectively. In either groups of wild-type EGFR
or mutant EGFR, gefitinib and erlotinib did … Erlotinib and gefitinib treatments do not result in …

… To the best of our knowledge, this is the first study worldwide to compare the efficacy of
erlotinib, gefitinib, and afatinib in patients with rare and common EGFR mutations. …

… shows the importance of EGFR mutation testing and patient selection according to these test
results for use of erlotinib, as for gefitinib. By comparison with PFS for gefitinib (10.4 months …

… We identified secondary EGFR mutations in three of six individuals whose disease progressed
on either gefitinib or erlotinib (Table 1). Brief case histories of these three patients are …

… EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib, patients with metastatic EGFR
mutation-… effective platinum doublet in patients with EGFR mutation-positive lung cancer. To …

… Other secondary mutations (D761Y and L747S) are rare. Our goal was to … of erlotinib 150
mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib …

… of uncommon EGFR mutations (13). This question cannot be addressed in this meta-analysis …
gefitinib and erlotinib as most of the included RCTs excluded uncommon EGFR mutations. …

… EGFR tyrosine kinase inhibitors. Our observation, together with data from recent reports,1,4
may help clarify the role of EGFR mutations in the development of EGFR-… tinib or erlotinib. By …

… receive erlotinib (150 mg per day) or gefitinib (250 mg per day) orally until disease progression
or unacceptable toxicity. We aimed to determine whether erlotinib is superior to gefitinib …

… to EGFR mutation types. In the subgroup of patients with Del19, the median PFS times for
afatinib, gefitinib, and erlotinib … For the subgroup of uncommon EGFR mutations, the afatinib …